SK Biopharm to Pioneer New Drug Development Using miRNA Technology
[Asia Economy Reporter Chunhee Lee] SK Biopharm is embarking on the development of innovative new drugs incorporating miRNA (microRNA) technology.
On the 5th, SK Biopharm announced that it recently signed a joint research and development agreement with BioOrchestra, a company developing RNA (ribonucleic acid)-based treatments for brain diseases. The two companies plan to discover new drug candidates targeting miRNA for epilepsy. miRNA is a type of RNA that regulates gene expression and protein production, attracting attention as a substance capable of diagnosing and treating various diseases.
Going forward, BioOrchestra will utilize its proprietary platform technology to select and synthesize substances, while SK Biopharm will be responsible for efficacy verification and preclinical trials. BioOrchestra possesses not only therapeutic development technology using antisense oligonucleotides (ASO) but also a system (BDDS) that enables RNA drugs to cross the blood-brain barrier and be delivered to brain cells, raising expectations for synergy through mutual cooperation.
In particular, through this contract, SK Biopharm has secured joint patent rights and licenses for the discovered new drug candidates. The company plans to expand indications to various central nervous system diseases in the future.
Ryu Jin-hyup, CEO of BioOrchestra, said, “Through collaboration with SK Biopharm, which has extensive experience in new drug development, we hope to provide excellent treatments more quickly to patients with intractable central nervous system diseases.”
Hot Picks Today
![About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]](https://cwcontent.asiae.co.kr/asiaresize/93/2026051416263163580_1778743590.jpg)
About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- "Envious of Korean Daily Life"...Foreign Tourists Line Up in Central Myeongdong from Early Morning [Reportage]
- "Anyone Who Visited the Room Salon, Come Forward"… Gangnam Police Station Launches Full Staff Investigation After New Scandal
- Did Samsung and SK hynix Rise Too Much?... Foreign Assets Grow Despite Selling [Weekend Money]
Jungwoo Cho, CEO of SK Biopharm, said, “SK Biopharm is enhancing research and development (R&D) innovation through partnerships with companies possessing promising technologies,” adding, “We will continuously expand our innovative new drug pipeline by incorporating next-generation technologies.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
